Natco Pharma Ltd (NSE: NATCOPHARM) and Symbiotec Pharmalab (NSE: SYMBIOTEC) are both listed in the Medicinal Chemicals and Botanical Products industry. Natco Pharma has a market capitalisation of ₹15,414 Cr and Symbiotec Pharmalab ₹7,871 Cr, as of 9 Nov 2026. Their P/E ratios are 9.9 and 64.5 respectively.
| Metric | Natco Pharma | Symbiotec Pharmalab |
|---|---|---|
| NSE Symbol | NATCOPHARM | SYMBIOTEC |
| BSE Code | 524816 | 544889 |
| Share Price | ₹805.00 | ₹1,546.20 |
| Market Cap | ₹15,414 Cr | ₹7,871 Cr |
| P/E Ratio | 9.9 | 64.5 |
| Return on Equity | 16.85% | — |
| Return on Assets | 7.98% | 6.96% |
| Dividend Yield | 0.57% | — |
| Beta (1Y) | 0.23 | -3.22 |
| 1-Year Price Change | -3.2% | — |
| 3-Month Price Change | -11.6% | — |
| 52-Week Range | ₹773.60 – ₹1,226.80 | ₹934.20 – ₹1,609.00 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹735 Cr | ₹280 Cr |
| Quarterly Net Profit | ₹207 Cr | ₹52 Cr |
| Net Margin | 28.1% | 18.5% |
| EPS (Basic, Quarter) | ₹11.53 | ₹8.20 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Indore, Madhya Pradesh |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and in…
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufact…
Natco Pharma has a market capitalisation of ₹15,414 Cr, against ₹7,871 Cr for Symbiotec Pharmalab as of 9 Nov 2026, about 2.0 times the size by market cap.
Natco Pharma has a P/E of 9.9 and Symbiotec Pharmalab a P/E of 64.5 as of 9 Nov 2026.
Natco Pharma reported revenue of ₹735 Cr and net profit of ₹207 Cr for Q1 FY27. Symbiotec Pharmalab reported revenue of ₹280 Cr and net profit of ₹52 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.